Head-To-Head Analysis: CION Investment (NYSE:CION) vs. Advanced Medical Isotope (OTCMKTS:RDGL)

CION Investment (NYSE:CION) and Advanced Medical Isotope (OTCMKTS:RDGL) are both small-cap finance companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Profitability

This table compares CION Investment and Advanced Medical Isotope’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CION Investment	10.59%	12.02%	4.91%
Advanced Medical Isotope	-6,144.90%	N/A	-113.56%

Insider and Institutional Ownership

32.0% of CION Investment shares are held by institutional investors. 0.6% of CION Investment shares are held by insiders. Comparatively, 18.5% of Advanced Medical Isotope shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

CION Investment has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500. Comparatively, Advanced Medical Isotope has a beta of -0.5, indicating that its share price is 150% less volatile than the S&P 500.

Earnings & Valuation

This table compares CION Investment and Advanced Medical Isotope”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CION Investment	$252.43 million	1.98	$33.90 million	$0.51	18.79
Advanced Medical Isotope	$30,000.00	1,058.26	-$2.91 million	N/A	N/A

CION Investment has higher revenue and earnings than Advanced Medical Isotope.

Analyst Recommendations

This is a summary of recent recommendations for CION Investment and Advanced Medical Isotope, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CION Investment	1	1	0	1	2.33
Advanced Medical Isotope	0	0	0	0	0.00

CION Investment presently has a consensus price target of $8.50, indicating a potential downside of 11.32%. Given CION Investment’s stronger consensus rating and higher probable upside, equities analysts plainly believe CION Investment is more favorable than Advanced Medical Isotope.

Summary

CION Investment beats Advanced Medical Isotope on 10 of the 12 factors compared between the two stocks.

About CION Investment

CION Investment Corporation is a business development company. It specializes in investments in senior secured loans, including unitranche loans, First Lien, second lien loans, long-term subordinated loans, and mezzanine loans; equity interests such as warrants or options; and corporate bonds; and other debt securities in middle-market companies. The firm invests in growth capital, acquisitions, leveraged buyouts, market/product expansion, refinancing and recapitalization. The fund also invests up to 30 percent of their assets opportunistically in other types of investments, including the securities of larger public companies and foreign securities. It also makes investments in the secondary loan market. The fund does not invest in start-up companies, turnaround situations, or companies with speculative business plans. The fund prefers to invest in high tech industries, healthcare, pharmaceuticals, business services, media, chemicals, plastic, rubber, telecommunication, consumer services, advertising, printing and publishing, consumer goods, durables, diversified financials, and other industries. It also invests in homebuilding, restaurants, beverage and tobacco bars, broadcasting, distributors, Non-durable good distribution, food beverage and tobacco, energy, oil gas and consumables fuels, insurance, aerospace and defense, industrial machinery, paper and forest product machinery, information technology, metals and mining, and real estate. It primarily seeks to invest in the United States. The fund seeks to invest between $5 million and $50 million in companies with an EBITDA between $25 million and $75 million with average targeted hold of $25 million. It also purchases minority interests in the form of common or preferred equity in the target companies, typically in conjunction with its debt investments or through a co-investment with a financial sponsor. The fund seeks to exit its investments through an initial public offering of common stock, a merger, a sale, or other recapitalization.

About Advanced Medical Isotope

Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.